Vanta Bioscience Limited (BOM:540729)
India · Delayed Price · Currency is INR 26.88
-1.41 (-4.98%)
At close: Aug 1, 2025
Intra-Cellular Therapies Revenue
Vanta Bioscience had revenue of 10.70M INR in the half year ending September 30, 2024, a decrease of -62.24%. This brings the company's revenue in the last twelve months to 45.88M, down -55.31% year-over-year. In the fiscal year ending March 31, 2024, Vanta Bioscience had annual revenue of 97.23M with 54.92% growth.
Revenue (ttm)
45.88M
Revenue Growth
-55.31%
P/S Ratio
8.18
Revenue / Employee
432.15K
Employees
48
Market Cap
169.67M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 97.23M | 34.47M | 54.92% |
| Mar 31, 2023 | 62.76M | -37.42M | -37.36% |
| Mar 31, 2022 | 100.18M | -331.32K | -0.33% |
| Mar 31, 2021 | 100.51M | -40.93M | -28.94% |
| Mar 31, 2020 | 141.44M | 17.19M | 13.84% |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Reliance Industries | 9,765.41B |
| HDFC Bank | 2,736.06B |
| Bharti Airtel | 1,729.85B |
| Tata Consultancy Services | 2,561.48B |
| ICICI Bank | 2,054.85B |
| State Bank of India | 3,429.39B |
| Infosys | 1,672.76B |
| Hindustan Unilever | 638.72B |